Dual inhibition of CB 1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID‐19-Reference-Cited by-同舟云学术

Dual inhibition of CB 1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID‐19

Published:2021-04-17 Issue: Volume: Page:
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:British J Pharmacology

Author:

Cinar Resat¹^ORCID,Iyer Malliga R.²,Kunos George³

Affiliation:

1. Section on Fibrotic Disorders National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH) Bethesda Maryland USA

2. Section on Medicinal Chemistry National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH) Bethesda Maryland USA

3. Laboratory of Physiologic Studies National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH) Bethesda Maryland USA

Funder

National Institute on Alcohol Abuse and Alcoholism

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bph.15461

Reference54 articles.

1. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

2. Synthetic cannabinoid induced acute respiratory depression: Case series and literature review

3. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis